Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
Angela GengeGary L PatteeGen SobueMasashi AokiHiide YoshinoPhilippe CouratierChristian LunettaSusanne PetriDaniel SelnessSachin BidaniManabu HiraiTakeshi SakataAlejandro SalahStephen AppleArt WamilAlexander KalinCarlayne E JacksonPublished in: Muscle & nerve (2022)
This study indicated that oral edaravone was well tolerated during 48 wk of treatment, with no new safety concerns identified.